Algos | News and Events

Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO

admin — Thu, 01 Oct 2009 14:26:02 +0000

Algos Preclinical Services is pleased to announce Dr. Ganesh Iyer as its new president and CEO. Dr. Iyer will assume his new responsibilities immediately.

“We were incredibly fortunate to have attracted such a uniquely qualified executive as Dr. Iyer to lead Algos.” stated Gary Smaby, Algos Board Chair and managing partner for Quatris Fund, the Company’s lead investor. “Dr. Iyer possesses the rare combination of scientific expertise and business acumen needed to lead Algos in the deployment of the Company’s new service-based CRO model focused on assisting leading pharmaceutical companies in bringing their technological breakthroughs to the marketplace.” adds Mr. Smaby.

Until recently, Dr. Iyer was Director of Strategic Analysis and Business Operations at MDS Pharma Services. Dr. Iyer has over 16 years of strategic and business development experience with prominent biotech and high-tech companies ranging from R&D start-ups to F500 companies, including ZymoGenetics/Novo Nordisk, Xcyte Therapies, SkeleTech, MDS Pharma Services and Microsoft. Dr. Iyer holds a Ph.D. in Chemical Engineering from Purdue University and an M.B.A. from Seattle University.

“I am very excited about joining Algos and look forward to working with an excellent team to achieving our mission and goal to become the premier preclinical in vivo pain research services company.” commented Dr. Iyer.

Bola Taiwo, PhD hired as Director of Physiology

admin — Fri, 21 Aug 2009 19:39:09 +0000

Algos Preclinical Services continues to invest in critical personnel and equipment as a part of its ongoing program to enhance the company’s value proposition and as it completes its shift to a purely service based contract research organization. After significant investment in lab facilities and equipment, Algos has been able to consistently grow its pharmacology business. Algos is now able to expand its service portfolio by growing its physiology program. Dr. Dan Menard, CEO, summed it up when he said “We are leaders in behavioral pain pharmacology. It’s time to take the next step with our pain physiology group.” As a pivotal part of this initiative, Algos is pleased to announce the addition of Dr. Bola Taiwo to our leadership team. Bola’s career spans both academic and commercial research. After obtaining his PhD in pharmacology, Bola pursued postdoctoral studies in Neuroscience at the University of Missouri-Kansas City and the University of Minnesota. His research in the academia focused on the neurobiology of pain and analgesia, neuroimmunologic regulation of pain, and neurobehavioral studies of novel compounds with central nervous system targets. After a stint in the academia, Bola joined Guidant Corporation (now Boston Scientific) where he served as Senior Scientist and Study Director in neurostimulation. More recently, Bola served as Study Director for cardiovascular, respiratory, and CNS safety pharmacology studies at Covance. Dr. Taiwo will lead our growing physiology group.

Scientists to present at Society For Neuroscience in Chicago

admin — Thu, 16 Jul 2009 21:21:53 +0000

Algos Preclinical Services will have a significant presence at the largest CNS conference in the USA, the Society for Neuroscience, in Chicago from October 17-21, 2009. Three posters in the area of preclinical in vivo pain research will be presented. In addition, booth #600 on the exhibit floor has been reserved for Algos to interact with our customers. Drop by, meet our new people, and hear firsthand how we can help your preclinical discovery program meet its goals.

CRO changes name

admin — Fri, 20 Mar 2009 21:23:50 +0000

To complete the process of converting to that of a contract research service provider, Algos Therapeutics, Inc. will now be conducting business as Algos Preclinical Services. Frank Eichmann, Director of Marketing, summed it up when he said, “Expertise in pain, stellar service and definitive results” are very important in this space; our brand and marketing efforts need to establish that we are now focused purely on providing contract research services for our customers. They are our focus from this point forward.” The company is not undergoing a legal name change, but rather is repositioning its public persona. The change will therefore not require the revising of any service agreements between Algos and its customers.

Dr. Pomonis brought in to lead Technical Development

admin — Mon, 22 Sep 2008 21:24:55 +0000

James Pomonis, PhD has been named Director of Technical Development. Dr. Pomonis has a long career in research in both pain and behavioral pharmacology. Most recently Dr. Pomonis was at Empi, Inc. where he directed clinical research activities for a number of pain management programs. Dr. Pomonis has an extensive background in preclinical in vivo pain research and as such, Algos is very pleased to have his guidance on the Senior Management Team.